Strategies for Neuroprotection, Relapse Prevention, and Mortality Reduction in Patients with Schizophrenia

Released On
May 11, 2020

Expires On
May 11, 2021

Media Type
Internet

Completion Time
60 minutes

Specialty
Psychiatry

Topic(s)
Schizophrenia

Scroll to the Bottom of this Information to Begin this Course

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati, Medical Education Resources (MER), and CMEology.


This activity is supported by an educational grant from Alkermes, Inc. and Otsuka America Pharmaceutical, Inc. and Lundbeck.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)
  • Nurses — 1.0 Nursing Contact Hour

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity has been designed to meet the educational needs of psychiatrists and advanced practice psychiatric clinicians who care for patients with schizophrenia.

Program Overview

Only a minority of patients with schizophrenia consistently adhere to their oral antipsychotics. Long-acting injectable (LAI) formulations of antipsychotics improve patient outcomes through both neuroprotection and improved adherence. To ensure that more patients with schizophrenia are offered the opportunity to take LAIs, clinicians who provide psychiatric care must possess accurate information about this important treatment option. In this activity, an expert faculty member will discuss the safety and tolerability of LAIs; their role in the treatment of first-episode psychosis, as well as later in the course of schizophrenia; the selection of an LAI; and strategies for discussing the option of LAIs with patients. Two patient cases will be presented to illustrate the use of LAIs in common clinical scenarios.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Describe the efficacy, safety, and tolerability profiles of LAI antipsychotics, including similarities and differences with oral formulations
  • Distinguish between adherence levels for LAI vs oral antipsychotics
  • Illustrate the benefits of LAI antipsychotics, particularly regarding neuroprotection
  • Assess the role of LAI antipsychotics early in schizophrenia, including first-episode psychosis

Faculty

Henry A. Nasrallah, MD

Vice Chair for Faculty Development and Mentorship
Professor of Psychiatry, Neurology, and Neuroscience
Director, Neuropsychiatry and Schizophrenia Programs
University of Cincinnati College of Medicine

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati, Medical Education Resources (MER), and CMEology.

The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Credit Designation

The University of Cincinnati designates this online activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This CE activity provides 1.0 contact hour of continuing nursing education. Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299.

Disclosures of Conflicts of Interest

Henry A. Nasrallah, MD

  • Advisory Board/Speakers Bureau: Acadia, Alkermes, Inc., Allergan, Janssen, Neurocrine Biosciences, Otsuka America Pharmaceutical Inc. and Lundbeck, Sunovion Pharmaceuticals Inc., and Teva

CMEology planners: No financial relationships to disclose.

Barb Forney, University of Cincinnati: No financial relationships to disclose.

Bruce Gebhardt, MD; Professor, University of Cincinnati: No financial relationships to disclose.

MER content reviewers: No financial relationships to disclose.

Instructions for Participation and Credit

There are no fees for participating in and receiving credit for this activity. During the period May 11, 2020 through May 11, 2021, participants must 1) read the learning objectives and faculty disclosures, 2) study the educational activity, 3) complete the posttest by recording the best answer to each question, and 4) complete the evaluation form.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better, with no more than 3 attempts.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of the planners. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

Contact Information

For questions about this activity, please contact CMEology at: info@cmeology.org.